Ciphergen Faces Nasdaq Delisting for Low Market Cap
The Nasdaq exchange told Ciphergen Biosystems last week that it risks being delisted because its market cap has remained below $50 million for 10 consecutive business days.
Ciphergen this week said it has until June 23 to regain compliance. Its market cap currently stands at $41.4 million, according to Nasdaq.
Bruker, Protein Discovery to Co-Market Imaging Mass-Spec Products
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
